 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Phase classification: Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19) (EUDRACT) - Dec 5, 2023
P=N/A, N=20, Not yet recruiting, Sponsor: The First People's Hospital of Chenzhou, Institute of Translational Medicine, University of South China; The First People's Hospital of Chenzhou, Inst
Phase classification: P1 --> P=N/A